Targeted measure of transcriptional activity related to hormone receptors
AssigneesBoard of Regents, The University of Texas System, Yale University
InventorsWilliam Fraser Symmans, Bruno Sinn, Christos Hatzis, Chunxiao Fu, Rosanna Lau
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER/PR index), and may have additional consideration for the proportion of ER gene (ESR1) RNA transcripts that contain a mutation relative to the value of the SETER/PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER/PR index.
Claims16
A kit for the measurement of expression levels of a plurality of endocrine genes from a sample from a subject, the kit comprising:
- (a) a set of 18 biotin-labeled probes for detecting mRNA expression levels of each one of SLC39A6, STC2, CA12, ESR1, PDZK1, NPY1R, CD2, MAPT, QDPR, AZGP1, ABAT, ADCY1, CD3D, NAT1, MRPS30, DNAJC12, SCUBE2, and KCNE4, wherein each of the probes of the set specifically hybridizes to one of SLC39A6, STC2, CA12, ESR1, PDZK1, NPY1R, CD2, MAPT, QDPR, AZGP1, ABAT, ADCY1, CD3D, NAT1, MRPS30, DNAJC12, SCUBE2, and KCNE4;
- and
- (b) a set of 10 biotin-labeled probes for detecting mRNA expression levels of each one of LDHA, ATP5J2, VDAC2, DARS, UCP2, UBE2Z, AK2, WIPF2, APPBP2, and TRIM2, wherein each of the probes of the set specifically hybridizes to each one of LDHA, ATP5J2, VDAC2, DARS, UCP2, UBE2Z, AK2, WIPF2, APPBP2, and TRIM2.
Dependencies are inferred from the claim text.